Weaver C. Barksdale & Associates, Inc. Abb Vie Inc. Transaction History
Weaver C. Barksdale & Associates, Inc.
- $109 Million
- Q1 2024
A detailed history of Weaver C. Barksdale & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Weaver C. Barksdale & Associates, Inc. holds 12,332 shares of ABBV stock, worth $2.12 Million. This represents 2.06% of its overall portfolio holdings.
Number of Shares
12,332
Previous 12,429
0.78%
Holding current value
$2.12 Million
Previous $1.93 Million
16.56%
% of portfolio
2.06%
Previous 1.88%
Shares
12 transactions
Others Institutions Holding ABBV
# of Institutions
3,651Shares Held
1.24BCall Options Held
15.5MPut Options Held
11.6M-
Vanguard Group Inc Valley Forge, PA170MShares$29.2 Billion0.62% of portfolio
-
Black Rock Inc. New York, NY143MShares$24.5 Billion0.61% of portfolio
-
State Street Corp Boston, MA78MShares$13.4 Billion0.64% of portfolio
-
Jpmorgan Chase & CO New York, NY51.3MShares$8.79 Billion0.85% of portfolio
-
Capital International Investors Los Angeles, CA48.1MShares$8.25 Billion1.81% of portfolio
About AbbVie Inc.
- Ticker ABBV
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,768,099,968
- Market Cap $303B
- Description
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...